Loading...
Publication
Influência do maleato de oclacitinib no hematócrito de cães atópicos
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.64 MB | Adobe PDF |
Abstract(s)
A dermatite atópica canina (DAC) é uma síndrome clínica complexa e multifatorial ligada a uma combinação de fatores genéticos e ambientais e traduz-se num dos principais motivos de consulta dermatológica. Devido ao seu impacto na qualidade de vida dos animais, o diagnóstico deve ser feito assim que possível. Este passa pela avaliação da história pregressa e exclusão dos diagnósticos diferenciais.
Um dos pontos-chave da terapêutica relativa à DAC é eliminar o prurido rapidamente de modo a prevenir danos, a curto e longo prazo, na barreira cutânea. Contudo, o tratamento deve ser, sempre que possível, etiológico.
O maleato de oclacitinib é um fármaco para administração oral inibidor das JAK (Janus Associated Kinases) autorizado para o controlo do prurido associado à DAC. No entanto, a citopénia é um dos potenciais efeitos adversos dos inibidores das JAK, nomeadamente dos inibidores da JAK2, pois a sinalização via JAK2 é mediada pela eritropoietina, trombopoietina e fator ativador de colónias de granulócitos.
Apesar da possibilidade do maleato de oclacitinib exercer influência sobre a eritropoiese, não existe um consenso sobre a necessidade de realizar uma monitorização laboratorial (hematologia, bioquímicas e urianálise) durante o período de tratamento. Contudo, estes exames complementares devem ser sempre realizados aquando do desenvolvimento de sinais de doença sistémica.
Foram diagnosticados 20 cães com DAC e realizados hematócritos antes e depois da terapêutica com oclacitinib, de forma a verificar a influência do fármaco sobre a eritropoiese. Na amostra estudada verificou-se que o medicamento em questão não exerceu influência significativa sobre o hematócrito. Averiguou-se também que este parâmetro não tem correlação relevante com a duração do tratamento, idade ou género dos animais tratados.
ABSTRACT - INFLUENCE OF OCLACITINIB MALEATE IN THE HEMATOCRIT OF ATOPIC DOGS - Canine atopic dermatitis (CAD) is a complex and multifactorial clinical syndrome linked to a combination of genetic and environmental factors and is one of the main requests for dermatological consultation. Due to its impact on the animals’ quality of life, the diagnosis should be made as soon as possible. This goes through the clinical history and exclusion of the differential diagnoses. One of the key points of CAD therapy is to eliminate pruritus quickly in order to prevent short and long-term damage to the skin barrier. Treatment must be whenever possible etiological. Oclacitinib maleate is an oral JAK inhibitor (Janus Associated Kinases) licensed for the control of pruritus associated with CAD. However, cytopenia is one of the potential adverse effects of JAK inhibitors, notably JAK2 inhibitors, since JAK2 signaling is mediated by erythropoietin, thrombopoietin and granulocyte colony-activating factor. However, there is no consensus on the need for laboratory monitoring (hematology, biochemistry and urinalysis) during the treatment period. Nonetheless, these complementary tests should always be performed when signs of systemic disease develop. 20 dogs with CAD were diagnosed and hematocrits were performed before and after oclacitinib therapy in order to verify the influence of the drug on erythropoiesis. In the sample studied, the drug in question had no significant influence on the hematocrit. It has also been found that this parameter does not have a relevant correlation with the treatment duration, age or gender of the treated animals.
ABSTRACT - INFLUENCE OF OCLACITINIB MALEATE IN THE HEMATOCRIT OF ATOPIC DOGS - Canine atopic dermatitis (CAD) is a complex and multifactorial clinical syndrome linked to a combination of genetic and environmental factors and is one of the main requests for dermatological consultation. Due to its impact on the animals’ quality of life, the diagnosis should be made as soon as possible. This goes through the clinical history and exclusion of the differential diagnoses. One of the key points of CAD therapy is to eliminate pruritus quickly in order to prevent short and long-term damage to the skin barrier. Treatment must be whenever possible etiological. Oclacitinib maleate is an oral JAK inhibitor (Janus Associated Kinases) licensed for the control of pruritus associated with CAD. However, cytopenia is one of the potential adverse effects of JAK inhibitors, notably JAK2 inhibitors, since JAK2 signaling is mediated by erythropoietin, thrombopoietin and granulocyte colony-activating factor. However, there is no consensus on the need for laboratory monitoring (hematology, biochemistry and urinalysis) during the treatment period. Nonetheless, these complementary tests should always be performed when signs of systemic disease develop. 20 dogs with CAD were diagnosed and hematocrits were performed before and after oclacitinib therapy in order to verify the influence of the drug on erythropoiesis. In the sample studied, the drug in question had no significant influence on the hematocrit. It has also been found that this parameter does not have a relevant correlation with the treatment duration, age or gender of the treated animals.
Description
Dissertação de Mestrado Integrado em Medicina Veterinária
Keywords
dermatite atopia dermatologia hematócrito oclacitinib cão dermatitis atopy dermatology hematocrit dog
Pedagogical Context
Citation
Gomes, P.S.T.A. (2017). Influência do maleato de oclacitinib no hematócrito de cães atópicos. Dissertação de mestrado. Universidade de Lisboa, Faculdade de Medicina Veterinária, Lisboa.
Publisher
Universidade de Lisboa, Faculdade de Medicina Veterinária